Skip to main content
. 2023 Apr 19;9(5):e15211. doi: 10.1016/j.heliyon.2023.e15211

Table 2.

Summary results of seroconversion discriminating according to the SARS-CoV-2 vaccine received.

Dose 1 Dose 2
COVID19 Vaccine anti-SPIKE IgGa IgGb (UI ml−1) anti-SPIKE IgGa IgGb (UI ml−1) n
Sputnik 75% 164 ± 39 100% 414 ± 49 16
AstraZeneca 80 250 ± 56 100% 416 ± 44 15
Sinopharm 25% 70 ± 45 88% 213 ± 36 16

n Individuals tested.

a

Percentages of seroconversion post-COVID 19 vaccination.

b

Anti-SPIKE IgG titer in blood serum.